Targeting tumor angiogenesis with histone deacetylase inhibitors. - Wikidata - wikimedia - TriplyDB

Targeting tumor angiogenesis with histone deacetylase inhibitors.

Targeting tumor angiogenesis with histone deacetylase inhibitors.

http://www.wikidata.org/entity/Q37359115

about

Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents Clinical use and applications of histone deacetylase inhibitors in multiple myeloma HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases Current insights into the molecular mechanisms of hypoxic pre- and postconditioning using hypobaric hypoxia Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo Paradoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphoma The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Chemotaxis in cancer Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.Crosstalk between the DNA damage response, histone modifications and neovascularisation.Development of HIF-1 inhibitors for cancer therapy Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Vascular endothelial growth factor receptor-2 in breast cancer.Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon.A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening.A novel mechanism involving coordinated regulation of nuclear levels and acetylation of NF-YA and Bcl6 activates RGS4 transcription.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia.Hdac-mediated control of endochondral and intramembranous ossification HEXIM1 down-regulates hypoxia-inducible factor-1α protein stability.The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis.Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.Promoting brain remodeling to aid in stroke recovery.Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.HIF1α protein stability is increased by acetylation at lysine 709.A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.

P2860

Q24618224-6C5399BF-C671-41E9-BEE5-DE190CA56BB8 Q26744212-5043E7D3-ED43-4C79-905E-2119A60D677F Q26745930-7845D826-07FD-4C41-838B-A885AE8548F0 Q26766640-02EDFC00-5795-4919-9D85-BF367DBD06C5 Q26777973-4E2A049C-865E-42AA-9B8C-09241893ED14 Q26783014-7C8112CD-3EFD-457C-A0F7-28E9A728DF28 Q27327201-8A7CEB43-455C-42AD-BBE6-4866B446C689 Q28482468-9CF07242-444E-474F-9978-407DC79F8AEA Q28535447-5F7B6E18-71DF-4A26-A691-66482E612615 Q28542639-17C707A5-FF54-4AED-81FC-DA2C59B7DEFA Q30538453-2E3E0B06-0759-437A-9371-3A2D377A40D2 Q30578627-7B8F0F27-0A73-426A-8C81-51A09E3CA5EB Q33394023-D6D343D5-E318-49F6-B28A-583B7C787C67 Q33419840-2B34E001-278E-4E40-BC63-257A58A8FD93 Q33420276-637979B5-2200-4605-8214-17D1809383A7 Q33439519-7FEC705B-899A-4D45-8D8E-5B1FAF8C5F0A Q33439523-8DB4ADB8-29AA-4920-A886-40D061616163 Q33639330-08E26EEC-BC39-4BDC-B551-FFD9CA0D43FD Q33703381-C0EF64CE-3E74-4093-BFB4-9689C68498FD Q33705588-66FDA192-3BB8-4966-B8D2-45AEDAA10BA9 Q33829390-275AEC01-45A2-4128-9B19-BF301A810A3C Q33912620-87C9915C-D58F-4B6C-80F7-85FFF6D146B0 Q34009114-ADE408E1-C622-43E1-8BA7-C7DE851274B0 Q34143251-A3ECE6D2-FCF4-449A-ACE9-96F913451CC5 Q34144764-57FE1CC4-DE73-476A-B01C-7FDB9B42F8F9 Q34224278-5ED1541A-56D1-45FD-82D5-866847DDE2FD Q34371189-75711099-3A19-4DD2-8F43-CA770C2ECD1D Q34399444-0FD47A92-48CC-4014-A579-A0A0721E3836 Q35108007-E26CF84A-7748-4B2C-90C7-7923EAB86927 Q35434188-BA742622-C685-4024-B243-C8F221FF678E Q35516124-B81D0824-03B8-4183-8603-68BC20A40A87 Q35556841-883374E1-DD4B-49E3-A95D-84FA4E5F3ECD Q35602354-AEFDEB9A-84FE-45C3-ACA4-7FC26BB30E63 Q35749723-4AA0EF99-BD08-464C-8F6A-3A03067DCD48 Q35895346-025A622E-9A8E-456B-B36E-FD2254209F16 Q35953399-28AFF7B7-D94B-4032-9332-E3A0730723EA Q36052807-47F086EA-0F5C-48DB-89B5-6B70DBA2D9CF Q36282749-BD00549A-0077-407B-803C-7EFB10E5C78B Q36318890-7D17F643-6DDF-4D0E-BA39-C784DEA99E28 Q36337623-FD809660-153B-4C1C-A488-7DBD7121182B

P2860

Targeting tumor angiogenesis with histone deacetylase inhibitors.

http://www.wikidata.org/entity/Q37359115

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting tumor angiogenesis with histone deacetylase inhibitors.

@en

Targeting tumor angiogenesis with histone deacetylase inhibitors.

@nl

type

label

Targeting tumor angiogenesis with histone deacetylase inhibitors.

@en

Targeting tumor angiogenesis with histone deacetylase inhibitors.

@nl

prefLabel

Targeting tumor angiogenesis with histone deacetylase inhibitors.

@en

Targeting tumor angiogenesis with histone deacetylase inhibitors.

@nl

P1433

Q37359115-E72B55B6-DC0F-41EE-885A-D60651955E8F

P1476

Q37359115-C86D689B-7951-427B-A59F-8FDC63EEE30D

P2093

Q37359115-4F34821C-64C8-46F3-A2F5-F0EDB49E41F6

Q37359115-935360FF-2472-4D1A-B29D-1ECC0E70963F

Q37359115-C418B438-9AD6-475C-8699-BB664989E629

P2860

Q37359115-029F035D-0136-4983-A47C-99228618B4BC

Q37359115-05D17B8D-CE8E-4F2D-900E-839541962397

Q37359115-0673A240-83AA-4A93-8F63-B069212CA37E

Q37359115-07E3FF28-F9A6-45A7-8110-B045ED7D582D

Q37359115-0939549D-B6F4-4EE3-9FCC-8614BBCF6A0E

Q37359115-0AD95E4E-D4C6-40F1-B619-CA4D3AF285B1

Q37359115-0BBD50CD-5BC0-4562-A5C6-41709BF67109

Q37359115-0DF3EBD8-3503-4975-BE2D-E0C256D84368

Q37359115-0E276C97-35AA-4546-A8CD-2958DFAAAA88

Q37359115-1E4D82B6-55FF-4381-85F1-A458BF52CCB3

P304

Q37359115-05255B40-84FC-4BA0-A83F-82F5A615BDCA

P31

Q37359115-FA9A3BD2-AC33-4D4D-9063-4F84548F3572

P356

Q37359115-AEABB045-2CE9-4AA9-AC66-04EA65364F5A

P407

Q37359115-C506E100-18D9-4720-B47E-14C31A0936BB

P433

Q37359115-A2442779-F72C-4C13-B84F-58DDA74D610A

P478

Q37359115-945F84FD-A65A-4634-BDC2-5C98BF4E8981

P577

Q37359115-811B5D3B-B1FC-4114-97D3-42DB1309083F

P5875

Q37359115-1DC74624-AE21-400D-AD87-3DD71509B868

P698

Q37359115-80C5E5E7-E28C-445D-B1A8-EEA0A9C93E61

P932

Q37359115-7062A22A-EF2F-4109-8E2D-AA3C2D919380

P356

J.CANLET.2008.11.012

P1433

P1476

Targeting tumor angiogenesis with histone deacetylase inhibitors.

@en

P2093

Hans Hammers

http://www.w3.org/2001/XMLSchema#string

Leigh Ellis

http://www.w3.org/2001/XMLSchema#string

Roberto Pili

http://www.w3.org/2001/XMLSchema#string

P2860

FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity

FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor

Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Sorafenib in advanced hepatocellular carcinoma

Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family

Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression

Loss of PTEN facilitates HIF-1-mediated gene expression

P304

145-153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CANLET.2008.11.012

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

280

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23708065

http://www.w3.org/2001/XMLSchema#string

P698

19111391

http://www.w3.org/2001/XMLSchema#string

P932

2814368

http://www.w3.org/2001/XMLSchema#string